Senseonics (NYSE:SENS) announced that it made equity grants to new employees under its 2019 inducement plan. Germantown, Maryland-based Senseonics, which develops the Eversense family continuous glucose monitoring (CGM) systems, including the latest-generation Eversense E3 180-day CGM, made the equity grants in accordance with the NYSE American Company Guide Section 711(a). Get the full story at our sister […]
Wall Street Beat
Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
Orchestra BioMed today announced a slew of agreements, including a strategic collaboration with Medtronic (NYSE:MDT). The global strategic collaboration will progress the development of Orchestra BioMed’s BackBeat Cardiac Neuromodulation Therapy (CNT) as a potential treatment for hypertension in patients who are indicated for a cardiac pacemaker. Additionally, Orchestra BioMed closed a $110 million Series D […]
Acutus completes first closing in left-heart access portfolio sale to Medtronic
Acutus Medical (Nasdaq:AFIB) announced today that it completed the first of two closings in its portfolio sale to Medtronic (NYSE:MDT). Carlsbad, California–based Acutus announced in April that it entered into a definitive agreement to sell its left-heart access portfolio to Medtronic for $50 million. The company’s left-heart access portfolio includes its AcQCross line of sheath-compatible septal […]
Nasdaq grants Titan Medical 180-day extension to regain compliance
Titan Medical (Nasdaq:TMDI) announced today that it received an additional 180 days to regain compliance with the Nasdaq market. According to a news release, the Listing Qualifications Staff of The Nasdaq Stock Market notified the company that it received 180 extra calendar days — running through Dec. 26, 2022 — to evidence compliance with the […]
FDA clears Acutus’ AcQCross system for use with Boston Scientific’s Watchman
Acutus Medical (Nasdaq:AFIB) announced today that it launched an expanded suite of left-heart access products. Following expanded FDA clearance, Acutus launched the suite to now include the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Boston Scientific Watchman left atrial appendage closure device. Carlsbad, California-based Acutus designed the AcQCross […]
Bioventus restructures $315M CartiHeal acquisition
Bioventus (Nasdaq:BVS) amended the agreement for its pending acquisition of CartiHeal to defer a large chunk of payments. Durham, North Carolina-based Bioventus announced in April that it agreed to acquire the orthopedic implant maker in a deal worth at least $315 million. An amendment to the acquisition agreement reduces the closing payment to $50 million […]
Conmed completes $145M In2Bones acquisition
Conmed (NYSE:CNMD) announced today that it completed its previously announced acquisition of In2Bones Global. Largo, Florida–based Conmed announced last month that it intended to acquire upper extremities device maker In2Bones Global for $145 million. The $145 million figure was floated for the closing of the acquisition, with up to an additional $110 million in growth-based […]
Dexcom quadruples number of shares
Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down 3.4% […]
Masimo shareholders vote ‘no’ on executive pay
Masimo (Nasdaq: MASI) shareholders recently voted to advise against the company’s compensation package for top executives. About 52.6% of voting shareholders voted against the patient monitoring tech company’s handling of executive pay in what’s known as the Say-on-Pay vote, according to vote results of the May 26 meeting filed with the SEC yesterday. The vote […]
Will Johnson & Johnson buy Boston Scientific?
Needham & Co. analyst Mike Matson today upgraded his rating of Boston Scientific (NYSE:BSX) shares to Buy, partly because he thinks it’s an acquisition target for Johnson & Johnson (NYSE:JNJ). Said Matson: “If JNJ decides to acquire a large medtech company, we believe that BSX could be a good fit.” BSX shares were up more […]
Needham & Co. downgrades Medtronic, Zimmer Biomet shares
Needham & Co. Senior Research Analyst Mike Matson today downgraded his rating of Medtronic (NYSE:MDT) and Zimmer Biomet (NYSE:ZBH) shares to Hold, while Boston Scientific (NYSE:BSX) got an upgrade to Buy. MDT shares were down more than 1% to $97.98 apiece in morning trading, a day after Q4 earnings that missed The Street sent the […]
